P

Provention Bio Inc
F:2VB

Watchlist Manager
Provention Bio Inc
F:2VB
Watchlist
Price: 21.6 EUR -0.46% Market Closed
Market Cap: 2B EUR

Relative Value

There is not enough data to reliably calculate the relative value of 2VB.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2VB Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
158.7
Median 5Y
156.6
Industry
2.5
vs History
vs Industry
Median 3Y
-18
Median 5Y
-13
Industry
21.6
vs History
vs Industry
Median 3Y
-27.1
Median 5Y
-15.7
Industry
16.7
vs History
vs Industry
Median 3Y
-38.5
Median 5Y
-16.7
Industry
24
vs History
vs Industry
Median 3Y
16.8
Median 5Y
7.4
Industry
2.2
vs History
vs Industry
Median 3Y
147.7
Median 5Y
145.7
Industry
2.7
vs History
vs Industry
Median 3Y
184.4
Median 5Y
55.8
Industry
5.3
vs History
vs Industry
Median 3Y
-15
Median 5Y
-9.6
Industry
12.9
vs History
vs Industry
Median 3Y
-14.8
Median 5Y
-9.6
Industry
16.3
vs History
vs Industry
Median 3Y
-25.2
Median 5Y
-11.9
Industry
15.2
vs History
vs Industry
Median 3Y
-24.9
Median 5Y
-11.9
Industry
17.7
vs History
vs Industry
Median 3Y
29.3
Median 5Y
28.9
Industry
1.9

Multiples Across Competitors

2VB Competitors Multiples
Provention Bio Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Provention Bio Inc
F:2VB
1.9B EUR 171.9 -19.5 -16.3 -16.2
US
Eli Lilly and Co
NYSE:LLY
751.6B USD 15.3 67.7 36.3 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
377.4B USD 4.2 17.3 12.6 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.6 12.9 14.8
CH
Roche Holding AG
SIX:ROG
204.3B CHF 3.4 24.7 9.3 10.9
CH
Novartis AG
SIX:NOVN
188.5B CHF 4.4 18.4 10.8 14.5
UK
AstraZeneca PLC
LSE:AZN
162B GBP 4 28.2 130.7 197.2
US
Merck & Co Inc
NYSE:MRK
209.7B USD 3.3 12 8.9 10.8
IE
Endo International PLC
LSE:0Y5F
184.8B USD 79.7 -63.2 294 737.3
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 18.5 7.8 11
P/E Multiple
Earnings Growth PEG
US
P
Provention Bio Inc
F:2VB
Average P/E: 25.7
Negative Multiple: -19.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.7
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.6
18%
1
CH
Roche Holding AG
SIX:ROG
24.7
32%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
P
Provention Bio Inc
F:2VB
Average EV/EBITDA: 437
Negative Multiple: -16.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
P
Provention Bio Inc
F:2VB
Average EV/EBIT: 1 875.5
Negative Multiple: -16.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.5
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.8
11%
1
IE
E
Endo International PLC
LSE:0Y5F
737.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
11
10%
1.1